GASTRIC-INHIBITORY POLYPEPTIDE (GIP) RESPONSE IN DIABETES USING A HIGHLY SPECIFIC ANTISERUM

被引：11

作者：

ALAM, MJ ^{[1
]}

KERR, JI ^{[1
]}

CORMICAN, K ^{[1
]}

BUCHANAN, KD ^{[1
]}

机构：

[1] QUEENS UNIV BELFAST,DEPT MED,WELLCOME RES LABS,GROSVENOR RD,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND

来源：

DIABETIC MEDICINE | 1992年 / 9卷 / 06期

关键词：

GASTRIC INHIBITORY POLYPEPTIDE; DIABETES-MELLITUS; MOLECULAR FORM; GUT HORMONE; ENTEROINSULAR AXIS; GIP;

D O I：

10.1111/j.1464-5491.1992.tb01835.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Gastric inhibitory polypeptide (GIP), a hormone secreted from the proximal small gut, is recognized as a major component of the enteroinsular axis. However, circulating levels of GIP in diabetes have been reported to be exaggerated, normal or decreased following glucose ingestion, which may be due to the presence of variable crossreacting immunoreactive GIP forms in the circulation. We have raised an antibody (S705) which recognizes only 5 kDa GIP. Using this antiserum we have measured circulating GIP levels in 18 healthy volunteers, and 13 Type 2 diabetic and 9 Type 1 diabetic patients following ingestion of 75 g glucose. As expected, blood glucose levels and blood insulin levels are significantly abnormal in the diabetic groups. On the other hand, circulating GIP levels at all time-points and integrated incremental GIP over 120 min were not different from the control group. However, we cannot exclude the possibility that apparently normal immunoreactive GIP levels in diabetes might conceal subtle alterations in biological activity which could play a role in the pathogenesis of the disease.

引用

页码：542 / 545

页数：4

共 28 条

[1] Brown JC, Pederson RA, Jorpes JE, Mutt V., Preparation of highly active enterogastrone, Can J Physiol Pharamacol, 47, pp. 113-114, (1969)
[2] Jornvall H., Carlquist M., Kwuak S., Otte, McIntosh CHS, Brown JC, Mutt V., Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP), FEBS Lett, 123, pp. 205-210, (1981)
[3] Brown JC., Gastric Inhibitory Polypeptide, (1982)
[4] Creutzfeldt W., The incretin concept today, Diabetologia, 16, pp. 75-85, (1979)
[5] Creutzfeldt W., Ebert R., New development in the incretin concept, Diabetologia, 28, pp. 565-573, (1985)
[6] Schafer R., Schatz H., Stimulation of (pro‐) insulin biosynthesis and release by gastric inhibitory polypeptide in isolated islets of rat pancreas, Acta Endocrinol (Copenh), 91, pp. 493-500, (1979)
[7] Beck B., Gastric inhibitory polypeptide: a gut hormone with anabolic functions, J Mol Endocrinol, 2, pp. 169-174, (1989)
[8] Brown JC, Dryburgh JR, Ross SA, Dupre J., Identification and actions of gastric inhibitory polypeptide, Recent Prog Horm Res, 31, pp. 487-532, (1975)
[9] Jones IR, Owens DR, Luzio S., Williams S., Hayes TM., The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (noninsulin‐dependent) diabetes mellitus, Diabetologia, 32, pp. 668-677, (1989)
[10] May JM, Williams RH., The effect of endogenous gastric inhibitory polypeptide on glucose induced insulin secretion in mild diabetes, Diabetes, 27, pp. 849-855, (1978)

← 1 2 3 →